Apellis Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Apellis Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q3 2024.
  • Apellis Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 256 %, a 28.3% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 256 +56.5 +28.3% Sep 30, 2024
Q2 2024 249 +63.4 +34.1% Jun 30, 2024
Q1 2024 223 +27.6 +14.1% Mar 31, 2024
Q4 2023 196 -1.19 -0.61% Dec 31, 2023
Q3 2023 199 -0.13 -0.07% Sep 30, 2023
Q2 2023 186 -93.4 -33.5% Jun 30, 2023
Q1 2023 195 -409 -67.7% Mar 31, 2023
Q4 2022 197 -5.37K -96.5% Dec 31, 2022
Q3 2022 200 -4.92K -96.1% Sep 30, 2022
Q2 2022 279 -1.09K -79.6% Jun 30, 2022
Q1 2022 604 +130 +27.5% Mar 31, 2022
Q4 2021 5.56K +5.25K +1694% Dec 31, 2021
Q3 2021 5.12K +4.79K +1450% Sep 30, 2021
Q2 2021 1.37K +1.11K +420% Jun 30, 2021
Q1 2021 474 +259 +121% Mar 31, 2021
Q4 2020 310 +143 +85.4% Dec 31, 2020
Q3 2020 330 +240 +264% Sep 30, 2020
Q2 2020 263 +218 +479% Jun 30, 2020
Q1 2020 214 +188 +703% Mar 31, 2020
Q4 2019 167 +145 +662% Dec 31, 2019
Q3 2019 90.7 +69.7 +332% Sep 30, 2019
Q2 2019 45.5 Jun 30, 2019
Q1 2019 26.7 Mar 31, 2019
Q4 2018 22 Dec 31, 2018
Q3 2018 21 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.